Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	38.36	37.05	38.71	32.29	12.66
Other Amortization	0.28	0.26	0.55	0.56	0.1
Loss (Gain) From Sale of Investments	0.17	0.17	-0.18	-	-
Provision for Credit Losses	-2.04	-0.58	0.94	3.89	0.2
Stock-Based Compensation	3.18	3.06	1.48	0.44	0.04
Change in Accounts Payable	1.15	1.11	0.17	0.76	0.27
Change in Other Net Operating Assets	-7.31	-6.6	-1.01	-10.14	-2.25
Other Operating Activities	-9.32	-10.84	-12.44	-9.8	-1.86
Operating Cash Flow	23.87	23.16	28.42	17.01	8.89
Operating Cash Flow Growth	-29.04%	-18.50%	67.11%	91.23%	-
Net Decrease (Increase) in Loans Originated / Sold - Investing	-15.07	-39.3	-1.93	-125.24	-193.63
Investing Cash Flow	-15.07	-39.3	-1.93	-125.24	-193.63
Short-Term Debt Issued	-	50	-	-	-
Long-Term Debt Issued	-	159	82	58	-
Total Debt Issued	197	209	82	58	-
Long-Term Debt Repaid	-	-170	-74	-	-
Net Debt Issued (Repaid)	6.75	39	8	58	-
Issuance of Common Stock	30.81	39.59	7.22	4.51	301.38
Common Dividends Paid	-41.37	-41.63	-39.13	-28.17	-6.85
Other Financing Activities	-2.01	-2.32	-0.4	-0.63	-2.79
Financing Cash Flow	-5.82	34.64	-24.31	33.71	291.73
Net Cash Flow	2.98	18.5	2.18	-74.53	107
Cash Interest Paid	6.16	6.21	5.03	1.66	-

Updated May 7, 2025. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.

SEC Filings: 10-K · 10-Q